Ochi H, Hayashi T, Nakao K, Yayoi E, Kawahara T, Matsumoto K
J Natl Cancer Inst. 1978 Feb;60(2):291-3. doi: 10.1093/jnci/60.2.291.
Estrogen, progesterone, and androgen receptors (ER, PgR, and AR, respectively) were determined by dextran-coated charcoal assay analyzed with Scatchard plots in cytosols from 81 Japanese patients with breast cancer. For the estimations of PgR and AR, the following compounds were used: a synthetic progestin, [3H]R5020 (17,21-dimethyl-19-nor-4,9-pregnadiene-3,20-dione), not bound by corticosteroid-binding globulin; and a synthetic androgen, [3H]R1881 (17beta-hydroxy-17-methylestra-4,9,11-trien-3-one), not bound by human sex steroid plasma-binding protein. Forty-two of 81 of the cancers revealed measurable amounts of ER (greater than 2 fmoles/mg cytosol protein), whereas the rates of measurable amounts of PgR (greater than 5) and AR (greater than 5) were 27% (18/67) and 36% (17/47), respectively. PgR were found in 45% of cancer patients with ER, but in only 9% of the cancer patients without ER. AR were found in 50% of the cancer patients with ER, but in only 22% of the cancer patients without ER. These results are consistent with those reported by Western investigators.
采用葡聚糖包被活性炭分析法并通过Scatchard图分析,对81例日本乳腺癌患者细胞溶质中的雌激素、孕激素和雄激素受体(分别为ER、PgR和AR)进行了测定。为了测定PgR和AR,使用了以下化合物:一种合成孕激素[3H]R5020(17,21 - 二甲基 - 19 - 去甲 - 4,9 - 孕二烯 - 3,20 - 二酮),其不与皮质类固醇结合球蛋白结合;以及一种合成雄激素[3H]R1881(17β - 羟基 - 17 - 甲基雌甾 - 4,9,11 - 三烯 - 3 - 酮),其不与人类性类固醇血浆结合蛋白结合。81例癌症患者中有42例显示可检测到的ER量(大于2 fmol/mg细胞溶质蛋白),而可检测到的PgR量(大于5)和AR量(大于5)的比例分别为27%(18/67)和36%(17/47)。在有ER的癌症患者中,45%检测到PgR,但在无ER的癌症患者中仅9%检测到。在有ER的癌症患者中,50%检测到AR,但在无ER的癌症患者中仅22%检测到。这些结果与西方研究者报道的结果一致。